Recent Publications: 2009-Present
  • Alemayehu D, Alvir J, Chappell PB, Knirsch, CA. A quantitative approach to enhancing risk assessment and mitigation in drug development. Applied Clinical Trials. 2012; 21 (4) 33-35


  • Alemayehu A, Quinn J, Cook J, Kunkel M, Knirsch CA. A Paradigm Shift in Drug Development for Treatment of Rare Multidrug Resistant Gram-Negative Pathogens Clinical Infectious Diseases. 2012; doi: 10.1093/cid/cis503


  • Alemayehu D. Assessing exchangeability in indirect and mixed treatment comparisons. Comparative Effectiveness Research. 2011;1: 51 - 55


  • Alemayehu D. Perspectives on Pooled Data Analysis: the Case for an Integrated Approach. Journal of Data Science. 2011; 9(3): 399-426


  • Alemayehu D. Trends in Comparative Effectiveness Research. Biopharmaceutical Report. 2011; 18 (1): 15-21


  • Alemayehu D, Alvir J, Jones B, Willke R. Statistical Issues with the Analysis of Non-Randomized Studies in Comparative Effectiveness Research. J Manag Care Pharm. 2011;17(9-a):S22-S26.


  • Alemayehu D, Cappelleri, JC. Revisiting Issues, Drawbacks, and Opportunities with Observational Studies in Comparative Effectiveness Research. Journal of Evaluation in Clinical Practice. To Appear. 2011.


  • Alemayehu D, Sanchez R, Cappelleri, JC. Considerations on the Use of Patient-Reported Outcomes in Comparative Effectiveness Research. J Manag Care Pharm. 2011;17(9-a):S27-S33.


  • Alemayehu D, Levenstein M. "Toward a Pragmatic Policy on Authorship," Statistics, Politics, and Policy. 201r12; Vol. 2: Iss. 1, Article 6. DOI: 10.2202/2151-7509.1034. Available at: http://www.bepress.com/spp/vol2/iss1/6


  • Alemayehu D, Mardekian, J. Infrastructure Requirement for Secondary Data Sources in Comparative Effectiveness Research. J Manag Care Pharm. 2011;17(9-a):S16-S21.


  • Guo J, Alemayehu D, Shao Y. Tests for Normality Based on Entropy Divergences. Statistics in Biopharmaceutical Research. 2010; 2(3):408-418.


  • Alemayehu D, Andrews EN, Glue P, Knirsch CA. Considerations for the design and conduct of a pharmacovigilance study involving mass drug >dministration in a resource-constrained setting. PLoS Negl Trop Dis. 2010; 4(1):e564 20126267.


  • Alemayehu D. Evaluation of Reporting Bias in Postmarketing Risk Assessment Based on Spontaneous Reporting Systems. Pharmaceutical Medicine. 2009; 3(4):195-200.


  • Alemayehu D. Current Issues with Covariate Adjustment in the Analysis of Data from Randomized Controlled Trials. Am J Ther. 2011 Mar-Apr;18(2):153-7.